Magnetic resonance imaging contrast using arabinogalactan as carrier
A technology of arabinogalactan and magnetic resonance imaging, which is applied in preparations for in vivo tests and pharmaceutical formulations, can solve problems such as increased toxicity, easy cross-linking, and reduced relaxation efficiency of contrast agents, and achieves improved Effects of imaging contrast, good selectivity, and long-term stable imaging window
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0053] Preparation of arabinogalactan by ethylenediamine-modified gadolinium diethylenetriaminepentaacetate complex (Gd-DTPA-CMAGA) contrast agent for magnetic resonance imaging
[0054] a) 1g of DTPA was dissolved in a mixed solution of 4.8ml of acetonitrile and 5.4ml of triethylamine, and the temperature was raised to 55°C. After DTPA was completely dissolved, 0.371g of DCC and 0.207g of HONSu were added at the same time, stirred at room temperature for 1.5h, and filtered to obtain DTPA- ONSu solution.
[0055] b) Dissolve 6g of arabinogalactan in 50ml of 6mol / L NaOH solution at 0°C, then add 12.3g of monochloroacetic acid, stir at 60°C for 50min, precipitate with methanol, filter, and dry in vacuo to obtain carboxymethyl sylated arabinogalactan.
[0056] c) Dissolve 6 g of carboxymethylated arabinogalactan in deionized water, adjust the pH to 3 with 1 mol / L HCl, add 9.3 g of EEDQ methanol solution dropwise, and add 12.5 ml of ethylenediamine dropwise while stirring, Stir ...
Embodiment 2
[0060] Preparation of Arabinogalactan as a Contrast Agent for Magnetic Resonance Imaging via Manganese Diethylenetriaminepentaacetate Complex Modified with Ethylenediamine
[0061] a) Step a) in the same example 1.
[0062] b) Same as step b) in Example 1.
[0063] c) Same as step c) in Example 1.
[0064] d) Same as step d) in Example 1.
[0065] e) Dissolve 0.5g of the DTPA macromolecule ligand modified by arabinogalactan in d in 10ml of deionized water, add 3ml of 0.2mol / L MnCl 2 Solution (more than 20% of the ratio), adjust the pH value to 5.7 with 1mol / L NaOH, stir overnight at room temperature, dialyze, exchange the aqueous solution outside the dialysis bag until its longitudinal relaxation time T 1 More than 3000ms, lyophilized to obtain arabinogalactan modified by ethylenediamine diethylenetriaminepentaacetic acid manganese complex magnetic resonance imaging contrast agent.
Embodiment 3
[0067] Preparation of arabinogalactan as a contrast agent for magnetic resonance imaging via ethylenediamine-modified gadolinium ethylenediaminetetraacetate complexes
[0068] a) Dissolve 0.743g EDTA in a mixed solution of 4.8ml acetonitrile and 5.4ml triethylamine, raise the temperature to 55°C, after EDTA is completely dissolved, add 0.371g DCC and 0.207g HONSu at the same time, stir at room temperature for 1.5h, filter to obtain EDTA- ONSu solution.
[0069] b) Same as step b) in Example 1.
[0070] c) Same as step c) in Example 1.
[0071] d) Dissolve 1 g of the aminated arabinogalactan in c in 25 ml of deionized water, add 10 ml of the EDTA-ONSu solution in step a, adjust the pH to 10 with 6 mol / L NaOH, stir at room temperature for 24 hours, and pump under reduced pressure Acetonitrile was removed, dialyzed for 5 days, the solution in the osmotic bag was rotary evaporated at 55°C to a small volume, and freeze-dried to obtain the arabinogalactan-modified EDTA macromolecu...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com